Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca's Ticagrelor Gets Positive EU Recommendation, But FDA Could Catch Up Soon

This article was originally published in The Pink Sheet Daily

Executive Summary

Europe's CHMP recommends ticagrelor for patients with acute coronary syndromes, while FDA still grapples with lack of effect in North American patients.
Advertisement

Related Content

AstraZeneca Says Brilinta Premium Pricing Merited Based On Labeling
AstraZeneca Says Brilinta Premium Pricing Merited Based On Labeling
AstraZeneca's Brilique Approved In The EU
AstraZeneca's Brilique Approved In The EU
Same Data, Same Day, Different Decision: FDA, EMA On Roche's Protease Inhibitor Invirase
Same Data, Same Day, Different Decision: FDA, EMA On Roche's Protease Inhibitor Invirase
Clotbusting On The Clock: New Brands Must Establish Themselves Before Improved Plavix Diagnostics Do
Clotbusting On The Clock: New Brands Must Establish Themselves Before Improved Plavix Diagnostics Do
Brilinta Panel Leaves FDA With The Task Of Crafting Labeling That Describes Poor U.S Efficacy Results

Topics

Advertisement
UsernamePublicRestriction

Register

PS071227

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel